Retrospective analysis of elderly patients (pts) with primary epithelial ovarian cancer (EOC) age 70 or older.

Abstract

e15518 Background: EOC frequently affects older women with maximum incidence in the eighth decade of life. Elderly pts have been reported to receive suboptimal therapy due to concerns for toxicity. The purpose of the study is to evaluate how elderly EOC pts at Yale-New Haven Hospital (YNHH) tolerated standard chemotherapy with paclitaxel (P) and carboplatin (C). Methods: Pts age ≥ 70 years, diagnosed with EOC in years 1996-2009 were identified through the Tumor Board Registry of YNHH. Charts were reviewed to determine if any patients required a dose reduction or discontinuation of treatment. Demographic data and clinical data including stage, histology, grade, dose, cycles, need for dose reduction, toxicities, co-morbidities, progression-free (PFS) and overall survival(OS) were obtained. These factors were analyzed using the statistical software of SAS version 9.1 to determine if age plays a factor in the treatment and outcome of women receiving standard PC chemotherapy. Results: 78 of 100 pts identified received chemotherapy at YNHH, with 82% pts received C AUC = 5, 13% C AUC ≥ 6, 84% P 175 mg/m2, and 6% P 135 mg/m2. We found 87% pts completed 6 cycles of therapy, 21% pts required a dose reduction and 31% of dose reductions were due to hematologic toxicities. Pts were analyzed in age groups of 70-74, 75-79, and ≥ 80, with 42%, 27% and 31% of pts in each group respectively. There was no statistical difference between these groups in requiring dose reductions (18%, 24%, and 21%, p = 0.8819), however there was a significant difference in % of pts completing a total of 6 cycles (82%, 86%, and 96% respectively, p = 0.02). Univariate analyses were performed looking at dose reduction and cycle completion versus stage (p = 0.2 and p= 0 .5), histology (p = 0.9 and p = 0.3), and number of comorbidities (p = 0.2 and p = 0.7). Conclusions: The majority of pts age ≥ 70 completed planned 6 cycle of standard PC therapy and tolerated it well. Age should not be a limiting factor in recommending standard dose and number of cycles of chemotherapy for elderly EOC pts. No significant financial relationships to disclose.